Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis: Prostate/GU

C11-choline PET scan for prostate cancer patients with biochemical recurrence

Christopher Mitchell, Val Lowe, Joseph Hung, Eugene Kwon and R. Jeffrey Karnes
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 35;
Christopher Mitchell
1Mayo Clinic Rochester, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Val Lowe
1Mayo Clinic Rochester, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Hung
1Mayo Clinic Rochester, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene Kwon
1Mayo Clinic Rochester, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Jeffrey Karnes
1Mayo Clinic Rochester, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

35

Objectives Relapsing disease is a common and challenging form of prostate cancer encountered in the contemporary clinical setting. Distinguishing between localized cancer or systemic recurrence represents a important step in optimizing prostate cancer treatment. Therefore we sought to determine the performance of C11-choline for its ability to delineate prostate cancer distribution and extent after failed definitive therapy.

Methods Retrospective review of all prostate cancer patients who underwent evaluation using C11-choline PET/CT scan from 9/2007 to 11/2010 at the Mayo Clinic was performed. Statistical analysis was performed to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Results During the study interval, a total of 254 PET scans were performed on 231 patients. 196 scans were performed on patients with biochemical recurrence after primary treatment failure. In this setting C11-choline PET scanning yielded a sensitivity, specificity, PPV, and NPV of 93, 76, 89, and 82%, respectively. 61 of 196 (31%) PET scans performed were deemed clinically “useful” as defined by their ability to detect treatable lesions, not identified using conventional imaging, thereby triggering changes in clinical management. 35 patients ultimately underwent surgical resection of isolated recurrent lesions detected by C11-choline PET. In these patients the sensitivity and PPV of C11-choline PET was 88 and 94%, respectively.

Conclusions The operational performance of C11-choline PET for the evaluation of patients with recurrent prostate cancer supports the favorable claims regarding this technology reported in the literature to date. In addition, we find that C11-choline PET substantially enhances the rate of prostate cancer lesion detection by approximately 30% beyond what can be garnered using conventionally accepted imaging technologies

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
C11-choline PET scan for prostate cancer patients with biochemical recurrence
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
C11-choline PET scan for prostate cancer patients with biochemical recurrence
Christopher Mitchell, Val Lowe, Joseph Hung, Eugene Kwon, R. Jeffrey Karnes
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 35;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
C11-choline PET scan for prostate cancer patients with biochemical recurrence
Christopher Mitchell, Val Lowe, Joseph Hung, Eugene Kwon, R. Jeffrey Karnes
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 35;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis: Prostate/GU

  • Effect of docetaxel on metastatic tumor 18F-fluorocholine uptake in patients with hormone-refractory prostate cancer
  • Dual phase 18F-FDG PET/CT imaging in evaluation of “radio-recurrent” prostate cancer
  • Early dynamic PET/CT and 18F-FDG blood flow imaging in bladder cancer detection: A novel approach
Show more Oncology: Clinical Diagnosis: Prostate/GU

Prostate/GU

  • 177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
  • Factors influencing outcome post Radium 223 dichloride in castrate resistant prostate cancer- A review of some real world challenges
  • Initial experience with volumetric 18F-PSMA-1007 PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in biochemically recurrent prostate cancer
Show more Prostate/GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire